Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
Evelo Biosciences (Nasdaq:EVLO) will host a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 1:20 p.m. ET. The event will be available via live audio webcast on their website, with a replay accessible for 30 days after. Evelo is a clinical stage biotechnology company focused on developing orally delivered medicines targeting the small intestinal axis for systemic effects. Their pipeline includes four product candidates for treating inflammatory diseases and cancer, emphasizing effective and affordable therapies.
- None.
- None.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monday, September 27th, 2021 at 1:20 p.m. ET.
A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contacts:
Investors:
Kendra Sweeney, 239-877-7474
ksweeney@evelobio.com
Media:
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
When is the Evelo Biosciences fireside chat scheduled?
Where can I watch the Evelo Biosciences presentation?
What is the focus of Evelo Biosciences?
What products is Evelo Biosciences currently developing?
